Business Context and Reporting Period
This Form 8-K Current Report is filed by National Health Investors, Inc. (NHI), a Maryland corporation listed on the New York Stock Exchange. The report date is April 20, 2026, covering events occurring on April 20 and April 21, 2026. The filing primarily addresses executive leadership transitions within the finance department.
Key Financial Metrics
This filing is a current report regarding corporate governance and personnel changes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. No financial performance data is provided in this document.
Material Changes
The material change disclosed is the departure of the Chief Financial Officer and the appointment of a successor:
- Departure: John L. Spaid notified the Board on April 21, 2026, of his intention to retire as Executive Vice President of Finance, Chief Financial Officer, and Treasurer, effective July 1, 2026. The retirement is not due to any disagreement with the Company.
- Appointment: Todd Siefert was appointed on April 20, 2026, as Executive Vice President of Corporate Finance, effective June 1, 2026. He will assume the role of Chief Financial Officer upon Mr. Spaid's retirement.
Management Commentary, Risks, and Unusual Items
Compensation and Transition Arrangements
Todd Siefert (Incoming CFO):
- Base Salary: $500,000 annually.
- Signing Bonus: One-time payment of $100,000.
- Equity Grant: Option to purchase 50,000 shares of common stock, vesting over two years.
- 2026 Incentives: Eligible for a prorated performance-based cash bonus (max $490,000) and a prorated equity award (target value $437,500, split between time-based restricted stock and performance-based RSUs).
- Transition Agreement: Entered April 21, 2026, subject to a release of claims.
- Equity Vesting: Pre-January 1, 2026, unvested restricted stock awards vest in full. For awards granted on or after January 1, 2026, either one-sixth will vest (remainder forfeited) or a cash payment equal to one-sixth of the value will be made.
- Options: All outstanding options continue to vest and remain exercisable as scheduled.
- Benefits: Medical premiums covered until December 31, 2026, and eligibility for a prorated 2026 annual bonus.
- Restrictions: Six-month non-compete and non-solicitation period following retirement.
Risks and Contingencies
The filing notes that the benefits for Mr. Spaid are contingent upon his execution and non-revocation of a release of claims. No other material risks or contingencies are disclosed in this specific report.
Investor Verification Checklist
- Verify the exact effective dates of the CFO transition (June 1, 2026, for Siefert's interim role; July 1, 2026, for full CFO succession).
- Review the full text of the Transition Agreement and General Release (Exhibit 10.1) to understand specific forfeiture conditions for Mr. Spaid's post-2025 equity awards.
- Confirm the vesting schedule and performance metrics for Mr. Siefert's new equity grants and bonus targets.
- Check the press release (Exhibit 99.1) for any additional strategic context regarding the leadership change.